Sandbox:risk: Difference between revisions
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
*'''DNA index >1'''<br> | *'''DNA index >1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
{{familytree/end}} | |||
<br> | |||
{{familytree/start |summary=PE diagnosis Algorithm.}} | |||
{{familytree | | | | | | | | | | | | | | |,| B03 | | | | |B03= }} | |||
{{familytree | | | | | | | | | | | | | | |!| | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | |)| B05 | | | | | B05= | | | | | | }} | |||
{{familytree | | | | | | | | | |,|-| B01 |(| | | | | | | B01= | | | | | | }} | |||
{{familytree | | | | | | | | | |!| | | | |)| B02 | | | | | |B02= }} | |||
{{familytree | | | | | | | | | |!| | | | |!| | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | |!| | | | |`| B04 | | | | | B04= | | | | | }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | C01 |-|+|-| C02 |-| C03 | | | |C01= |C02= |C03= }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | |`|-| D01 |-| D02 | | | |D01= |D02= }} | |||
{{familytree/end}} | |||
Intermediate risk neuroblastoma patients include: | |||
Group 1 | |||
Patients with stage 2A/2B (<50% resected or Bx only) tumor, 0-12 years of age, irrespective of the grade, MYCNnot amplified | |||
Patients with stage 3 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified | |||
Patients with stage 3 tumor, 1-12 years of age, favorable histology, MYCNnot amplified | |||
Patients with symptomatic stage 4S, <365 days of age, favorable histology, DNA index >1, MYCNnot amplified | |||
Group 2 | |||
Patients with stage 3 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified | |||
Patients with stage 4 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified | |||
Patients with stage 4S tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified | |||
Group 3 | |||
Patients with stage 4 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified | |||
Patients with stage 3 tumor, 365-547 days of age, unfavorable histology, MYCN not amplified | |||
Patients with stage 4 tumor, 365-547 days of age, favorable histology, DNA index >1, MYCN not amplified | |||
Revision as of 01:40, 10 October 2015
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk neuroblastoma patients |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients include:
Group 1
Patients with stage 2A/2B (<50% resected or Bx only) tumor, 0-12 years of age, irrespective of the grade, MYCNnot amplified Patients with stage 3 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified Patients with stage 3 tumor, 1-12 years of age, favorable histology, MYCNnot amplified Patients with symptomatic stage 4S, <365 days of age, favorable histology, DNA index >1, MYCNnot amplified
Group 2
Patients with stage 3 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified Patients with stage 4 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified Patients with stage 4S tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified
Group 3
Patients with stage 4 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified Patients with stage 3 tumor, 365-547 days of age, unfavorable histology, MYCN not amplified Patients with stage 4 tumor, 365-547 days of age, favorable histology, DNA index >1, MYCN not amplified